

## **ASX Announcement and Media Release**

Date: 10 March 2003

### **Domantis announcement of ImClone Systems License Agreement**

Detailed below are the contents of a Domantis (in which Peptech holds a 36.1% interest) announcement being released today in the United Kingdom.

#### ***“Domantis Licenses Domain Antibody Technology to ImClone Systems Incorporated***

**Cambridge, UK and USA, March 10, 2003...** *Domantis Limited, the leading Domain Antibody (dAb) drug discovery company, has entered into a non-exclusive licensing agreement with ImClone Systems Incorporated. The deal enables ImClone Systems to select dAbs for therapeutic and research use from Domantis’ proprietary dAb libraries, which contain billions of different fully human Domain Antibodies. Domantis will receive technology license fees as well as milestones and royalties on any therapeutic dAb products developed by ImClone Systems.*

*Domantis CEO Robert Connelly said, ‘We are very pleased to establish this partnership with ImClone Systems, a leader in antibody therapeutics. This deal further underlines the value and potential of our unique dAb libraries, coming just four months after we entered a dAb research and development alliance with Abbott Laboratories. We anticipate signing a number of additional partnerships and licenses in the coming year. Domantis will apply the revenues derived from such agreements to support the discovery of proprietary Domantis drug candidates. We are currently working on 12 internal therapeutic projects and expect a number of these to enter pre-clinical studies in the coming fiscal year’.*

*Fully human dAbs are the smallest functional fragments of antibodies. They are less than one tenth the size of conventional antibodies and combine the best attributes of small molecule drugs (formulation and delivery versatility, broad target range, low cost) with those of full antibodies (enormous diversity, high specificity, lower toxicity). Domantis has created a range of large and highly diverse fully human dAb libraries that are a source of potent drug candidates.”*

For further information please contact:

STEPHEN KWIK  
MANAGING DIRECTOR  
PEPTECH LIMITED  
Ph (02) 9870 8788

Dr PAUL SCHOBER  
INVESTOR RELATIONS  
PEPTECH LIMITED  
Ph (02) 9870 8788

